Detalles de la búsqueda
1.
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
Diabetes Obes Metab
; 25(8): 2331-2339, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37184050
2.
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab
; 26(2): 758-762, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37881140
3.
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
Diabetes Obes Metab
; 25(7): 2038-2042, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36942888
4.
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab
; 25(7): 2043-2047, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36974373
5.
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.
J Am Heart Assoc
; 13(3): e031586, 2024 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38240199
6.
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials.
Diabetes Care
; 47(3): 501-507, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38252809
Resultados
1 -
6
de 6
1
Próxima >
>>